Ervogastat
Overview of the drug Ervogastat
| Ervogastat | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Ervogastat is an investigational drug that acts as a diacylglycerol O-acyltransferase 2 (DGAT2) inhibitor. It is being studied for its potential use in the treatment of non-alcoholic steatohepatitis (NASH), a progressive liver disease characterized by inflammation and fat accumulation in the liver.
Mechanism of Action[edit | edit source]
Ervogastat functions by inhibiting the enzyme DGAT2, which plays a crucial role in the synthesis of triglycerides. By blocking this enzyme, Ervogastat reduces the formation of triglycerides, thereby decreasing fat accumulation in the liver. This mechanism is particularly beneficial in conditions like NASH, where excessive fat deposition leads to liver damage.
Clinical Development[edit | edit source]
Ervogastat is currently undergoing clinical trials to evaluate its efficacy and safety in patients with NASH. The drug has shown promise in preclinical studies, demonstrating a significant reduction in liver fat content and improvement in liver histology.
Potential Benefits[edit | edit source]
The primary benefit of Ervogastat is its ability to target the underlying metabolic disturbances in NASH. By reducing liver fat, it may help to alleviate inflammation and fibrosis, potentially slowing the progression of the disease. This could lead to improved liver function and a reduction in the risk of cirrhosis and liver-related complications.
Side Effects[edit | edit source]
As with any investigational drug, the safety profile of Ervogastat is still being established. Common side effects observed in clinical trials include mild gastrointestinal disturbances, such as nausea and diarrhea. Ongoing studies aim to further elucidate the long-term safety and tolerability of the drug.
Future Directions[edit | edit source]
Research on Ervogastat is focused on optimizing its therapeutic potential and understanding its role in the broader context of metabolic diseases. Future studies may explore its use in combination with other therapies to enhance treatment outcomes for patients with NASH and related conditions.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
